The landscape of pharmacological interventions in combating obesity has long struggled
with the formidable challenge of balancing efficacy and safety, with weightloss drugs often …

The OASIS 1 trial by Filip K Knop and colleagues1 demonstrates the greatest magnitude of
weight loss to date among oral anti-obesity medications. 2− 4 In this randomised, double …

Semaglutide 2· 4 mg once weekly, an anti-obesity medication now submitted to regulators
across the USA and Europe, is generating much excitement and attention about the amount …

Obesity is a chronic, recurring, progressive disease and a major public health problem
associated with several other diseases that lead to disability, morbidity, and mortality. The …

The treatment of obesity can no longer be reduced to a simplistic view of weight loss.
Metabolic adaptation leads to systematic weight regain following weight-loss efforts, and …

In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major
adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …

Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …

Obesity is a chronic, relapsing disease associated with multiple complications and a
substantial morbidity, mortality and health care burden. Pharmacological treatments for …

The rapidly increasing prevalence of obesity and obesity-associated morbidity is causing an
ever-increasing global burden. Beyond lifestyle modifications, pharmacological approaches …